检索结果-南通市图书馆

Journal of Pharmaceutical Analysis 2011年第2期1卷 108-112页

作者： ming-yue li yu-hai tang xia liu hai-yan lu xi-yan shi Institute of Analytical Science Xi 'an Jiaotong University Xi'an 710061 China.

A novel high performance liquid chromatographic method was developed for the determination of 4-O- methylhonokiol in rabbit plasma and was applied to its pharmacokinetic investigation. Plasma samples were treated by one-fold volume of methanol and acetonitrile to remove the interference proteins. A reverse phase column of shiM- PACK VP-ODS （150 mm × 4.6 mm, 5.0 μm） was used to separate 4-O-methylhonokiol in the plasma samples. The detection limit of 4-O-methylhonokiol was 0.2 μg/L and the linear range was 0. 012 - 1. 536 mg/L. The good extraction recoveries were obtained for the spiked samples （84.7%, 89.3% and 87.7% for low, middle and high concentrations of added standards, respectively）. The relative standard deviation of intra-day and inter-day precisions was in the range from 0.6% to 13.5%. The pharmacokinetic study of 4-O-methylhonokiol was made and the results from the plasmaconcentration curve of 4-0-methylhonokiol showed a two-apartment open model. This work developed a sensitive, stable and rapid HPLC method for the determination of 4-O-methylhonokiol and the developed method has been successfully applied to a pharmacokinetic study of 4-O-methylhonokiol.

关键词： 4-O-methylhonokiol Cortex Magnoliae Officinalis high performance liquid chromatography pharmacokinetic

Design biodegradable Zn alloys: Second phases and their significant influences on alloy properties

在线全文

学校读者我要写书评

暂无评论

Bioactive Materials 2020年第2期5卷 210-218页

作者： Zhang-Zhi shi xi-xian Gao hai-Jun Zhang Xue-Feng liu Hui-yan li Chao Zhou yu-xia Yin lu-Ning Wang Beijing Advanced Innovation Center for Materials Genome Engineering Beijing Laboratory of Metallic Materials and Processing for Modern TransportationKey Laboratory for Advanced Materials Processing of Ministry of EducationSchool of Materials Science and EngineeringUniversity of Science and Technology BeijingBeijing100083China Department of Interventional and Vascular Surgery The Tenth People's Hospital of ShanghaiTongji UniversityShanghai200072China National United Engineering Laboratory for Biomedical Material Modification Branden Industrial ParkDezhou CityShandong251100China

Alloying combined with plastic deformation processing is widely used to improve mechanical properties of pure ***-cast Zn and its alloys are *** plastic deformation processing,no effective method has yet been found to eliminate the brittleness and even endow room temperature *** phase,induced by alloying,not only largely determines the ability of plastic deformation,but also influences strength,corrosion rate and *** second phase is important for designing biodegradable Zn *** this review,knowledge related to second phases in biodegradable Zn alloys has been analyzed and summarized,including characteristics of binary phase diagrams,volume fraction of second phase in function of atomic percentage of an alloying element,and so *** about second phases in Zn-li,Zn-Cu and Zn-Fe systems have been settled down,which benefits future *** effects of alloying elements and second phases on microstructure,strength,ductility,corrosion rate and cytotoxicity have been neatly ***,Mn,li,Cu and Ag are recommended as the major alloying elements,owing to their prominent beneficial effects on at least one of the above *** future,synergistic effects of these elements should be more thoroughly *** other nutritional elements,such as Fe and Ca,refining second phase is a matter of vital concern.

关键词： Biodegradable Zn alloys Alloy design Second phase Microstructure Comprehensive properties

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA yan ZHU Dong Shan CHEN Ren Bo shi Nan Nan liu Si Hong FAN Yi Pin WU Gui Hui yanG Pu Ye BAI Jiang Feng CHEN Hong CHEN li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU xiao Mei HU yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI liang JIN hai Hao LEI xiao li Chun yan li Min Qing li Qun tang li xian Yong liu Hong De liu Jin Ping liu Zhang MA yu Ting MAO Ya MO liu Fen NA Hui WANG Jing Wei SONG Fang li SUN Sheng WANG Dong Ting WANG ming Xuan WANG xiao yan WANG Yin Zhen WANG yu Dong WU Wei WU Lan Ping xiaO yan Hua xiE hai Jun XU Hong ming XU Shou Fang XUE Rui xia yanG Chun yanG Kai Jun yuAN Sheng li ZHANG Gong Qi ZHANG Jin Bo ZHANG lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG yan Ping WANG Yong yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

Data processing and data products from 2017 to 2019 campaign of astronomical site testing at Ali,Daocheng and Muztagh-ata

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第6期20卷 109-130页

作者： Zi-Huang Cao Jin-xin Hao lu Feng Hugh RAJones Jian li Jing Xu li-Yong liu Teng-Fei Song Jian-Feng Wang Hua-lin Chen yan-Jie Xue Huang Shen Yong-Heng Zhao Zhao-xiang Qi Jian-Rong shi yuan Tian Zheng Wang xia Wang Jin-liang Hou Jin-ming Bai Ji yang Xu Zhou Yong-Qiang Yao Jia Yin Ali Esamdin Guang-xin Pu Peng Wei Chun-hai Bai Guo-Jie Feng lu Ma Xuan Zhang yu liu Chong Pei Zhi-xia Shen yun-Ying Jiang Jian-Feng Tian xian-Qun Zeng Zhi-Gang Hou Xu yang Jun-Bo Zhang shi-Long liao Dong-Wei Fan yun-Fei Xu Jian-Ping xiong Tai-Sheng yan xi Zhang Chang-Hua li Yi-Han Tao Si-Cheng yu Zhi-Song Cao Hong-Shuai Wang National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100049China Shanghai Astronomical Observatory Chinese Academy of SciencesShanghai 200030China Centre for Astrophysics University of HertfordshireHatfieldUK School of Journalism Communication University of ChinaBeijing 100024China Nanjing Institute of Astronomical Optics&Technology Chinese Academy of SciencesNanjing 210042China xinjiang Astronomical Observatory Chinese Academy of SciencesUrumqi 830011China yunnan Observatories Chinese Academy of SciencesKunming 650216China Purple Mountain Observatory Chinese Academy of SciencesNanjing 210033China Beijing Kaiyang Space Technology Co. LtdBeijing 100085China

Based on previous site testing and satellite cloud data,Ali,Daocheng and Muztagh-ata have been selected as candidate sites for the Large Optical/Infrared Telescope(LOT) in *** present the data collection,processing,management and quality analysis for our site testing based on using similar *** analyze meteorological data,seeing,background light,cloud and precipitable water vapor data from 2017 March 10 to 2019 March *** also investigated the relative usefulness of our all-sky camera data in comparison to that from the meteorological TERRA satellite data based on a night-by-night comparison of the correlation and consistency between *** find a 6% discrepancy arising from a wide range of factors.

关键词： LOT Site-selection-data processing

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-li luo Yong-Heng Zhao Gang Zhao li-Cai Deng xiao-Wei liu Yi-Peng Jing Gang Wang Hao-Tong Zhang Jian-Rong shi xiang-Qun Cui Yao-Quan Chu Guo-Ping li Zhong-Rui Bai yue Wu yan Cai Shu-yun Cao Zi-Huang Cao Jeffrey L.Carlin hai-yuan Chen Jian-Jun Chen Kun-xin Chen li Chen Xue-Lei Chen xiao-yan Chen Ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui Yi-Qiao Dong Bing Du Dong-Wei Fan Lei Feng Jian-Ning Fu Peng Gao Xue-Fei Gong Bo-Zhong Gu yan-xin Guo Zhan-Wen Han Bo-liang He Jin-liang Hou Yong-Hui Hou Wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu Zhi-Ying Huo Lei Jia Fang-Hua Jiang xiang Jiang Zhi-Bo Jiang Ge Jin xiao Kong Xu Kong Ya-Juan Lei Ai-Hua li Chang-Hua li Guang-Wei li hai-Ning li Jian li Qi li Shuang li Sha-Sha li xin-Nan li yan li Yin-Bi li Ye-Ping li yuan liang Chien-Cheng lin Chao liu Gen-Rong liu Guan-Qun liu Zhi-Gang liu Wen-Zhi lu yu luo Yin-Dun Mao Heidi Newberg Ji-Jun Ni Zhao-xiang Qi Yong-Jun Qi shi-Yin Shen Huo-ming shi Jing Song Yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong tang Qing-Sheng Tao yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang hai Wang Hong-Chi Wang Jian Wang Jia-Ning Wang Jian-ling Wang Jian-Ping Wang Jun-xian Wang Lei Wang Meng-xin Wang Shou-Guan Wang Shu-Qing Wang xia Wang Ya-Nan Wang You Wang yue-Fei Wang You-Fen Wang Peng Wei ming-Zhi Wei Hong Wu Ke-Fei Wu Xue-Bing Wu yu-Zhong Wu xiao-Zheng xing ling-Zhe Xu xin-Qi Xu yan Xu Tai-Sheng yan De-Hua yang hai-Feng yang Hui-Qin yang ming yang Zheng-Qiu Yao Yong yu Hui yuan hai-Bo yuan hai-Long yuan Wei-Min yuan Chao Zhai En-Peng Zhang Hua-Wei Zhang Jian-Nan Zhang li-Pin Zhang Wei Zhang Yong Zhang yan-xia Zhang Zheng-Chao Zhang ming Zhao Fang Zhou Xu Zhou Jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Searching for ^(76)Ge neutrinoless double beta decay with the CDEX-1B experiment

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第10期48卷 11-22页

作者： Bing-Tao Zhang Jun-Zheng Wang li-Tao yang Qian yue Ke-Jun Kang yuan-Jing li hai-Peng An C.Greeshma Jian-Ping Chang yun-Huan Chen Jian-Ping Cheng Wen-Han Dai Zhi Deng Chang-Hao Fang xin-Ping Geng Hui Gong Qiu-Ju Guo Xu-yuan Guo li He Sheng-ming He Jin-Wei Hu Han-xiong Huang Tu-Chen Huang hai-Tao Jia xi Jiang S.Karmakar Hao-Bin li Jian-Min li Jin li Qian-yun li Ren-ming-Jie li Xue-Qian li yu-Lan li Yi-Fan liang Bin liao Fong-Kay lin shin-Ted lin Jia-Xuan liu Shu-Kui liu yan-Dong liu yu liu yuan-yuan liu Zhong-Zhi liu Hao Ma yu-Cai Mao Qi-yuan Nie Jin-Hua Ning Hui Pan Ning-Chun Qi Jie Ren xi-Chao Ruan Ze She Manoj Kumar Singh Tian-xi Sun Chang-Jian tang Wei-You tang yang Tian Guang-Fu Wang li Wang Qing Wang yu-Feng Wang yun-xiang Wang Henry-Tsz-King Wong shi-Yong Wu yu-Cheng Wu Hao-yang xing Rui Xu Yin Xu Tao Xue yu-lu yan Nan Yi Chun-Xu yu hai-Jun yu Jian-Feng yue ming Zeng Zhi Zeng Feng-Shou Zhang Lei Zhang Zhen-Hua Zhang Zhen-yu Zhang Kang-Kang Zhao ming-Gang Zhao Ji-Fang Zhou Zu-Ying Zhou Jing-Jun Zhou Key Laboratory of Particle and Radiation Imaging(Ministry of Education)and Department of Engineering Physics Tsinghua UniversityBeijing 100084 Department of Physics Tsinghua UniversityBeijing 100084 Institute of Physics Academia SinicaTaipei 11529 NUCTECH Company Beijing 100084 YaLong River Hydropower Development Company Chengdu 610051 College of Nuclear Science and Technology Beijing Normal UniversityBeijing 100875 College of Physics Sichuan UniversityChengdu 610065 School of Physics Peking UniversityBeijing 100871 Department of Nuclear Physics China Institute of Atomic EnergyBeijing 102413 Sino-French Institute of Nuclear and Technology Sun Yat-sen UniversityZhuhai 519082 School of Physics Nankai UniversityTianjin 300071 Department of Physics Banaras Hindu UniversityVaranasi 221005 Department of Physics Beijing Normal UniversityBeijing 100875

We operated a p-type point contact high purity germanium(PPCGe)detector(CDEX-1B,1.008 kg)in the China Jinping Underground Laboratory(CJPL)for 500.3 days to search for neutrinoless double beta(0νββ)decay of ^(76)Ge.A total of 504.3 kg⋅day effective exposure data was *** anti-coincidence and the multi/single-site event(MSE/SSE)discrimination methods were used to suppress the background in the energy region of interest(ROI,1989–2089 keV for this work)with a factor of 23.A background level of 0.33 counts/(keV⋅kg⋅yr)was *** lower limit on the half life of^(76)Ge 0νββdecay was constrained as T_(1/2)^(0ν)>1.0×10^(23)yr(90%C.L.),corresponding to the upper limits on the effective Majorana neutrino mass:<3.2–7.5 eV.

关键词： neutrinoless double beta decay CDEX point-contact germanium detector ^(76)Ge

The Lyman-alpha Solar Telescope(LST) for the ASO-S mission——Ⅱ. design of LST

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2019年第11期19卷 33-48页

作者： Bo Chen Hui li Ke-Fei Song Quan-Feng Guo Pei-Jie Zhang ling-Ping He Shuang Dai xiao-Dong Wang hai-Feng Wang Chun-Long liu Hong-Ji Zhang Guang Zhang yunqi Wang shi-Jie liu Hong-xin Zhang Lei liu shi-Lei Mao yang liu Jia-Hao Peng Peng Wang liang Sun yang liu Zhen-Wei Han yan-Long Wang Kun Wu Guang-xing Ding Peng Zhou xin Zheng ming-Yi xia Qing-Wen Wu Jin-Jiang xie Ya Chen Shu-Mei Song Hong Wang Bo Zhu Chang-Bo Chu Wen-Gang yang li Feng yu Huang Wei-Qun Gan Ying li Jing-Wei li Lei lu Jian-Chao Xue Bei-li Ying ming-Zhe Sun Cheng Zhu Wei-Min Bao Lei Deng Zeng-Shan Yin Changchun Institute of Optics FineMechanics and PhysicsChinese Academy of SciencesChangchun 130033China State Key Laboratory of Applied Optics Changchun 130033China Key Laboratory of Dark Matter and Space Astronomy Purple Mountain ObservatoryChinese Academy of SciencesNanjing 210034China School of Astronomy and Space Science University of Science and Technology of ChinaHefei 230026China xi’an Institute of Optics and Precision Mechanics Chinese Academy of SciencesXi’an 710119China Shandong University Weihai 264209China Innovation Academy for Microsatellites Chinese Academy of SciencesShanghai 201210China

As one of the three payloads for the Advanced Space-based Solar Observatory(ASO-S)mission,the Lyman-alpha(Lyα)Solar Telescope(LST)is composed of three instruments:a Solar Corona Imager(SCI),a LyαSolar Disk Imager(SDI)and a full-disk White-light Solar Telescope(WST).When working in-orbit,LST will simultaneously perform high-resolution imaging observations of all regions from the solar disk to the inner corona up to 2.5 R⊙(R⊙stands for the mean solar radius)with a spatial resolution of 4.8′′and 1.2′′for coronal and disk observations,respectively,and a temporal resolution of 30–120 s and 1–120 s for coronal and disk observations,*** maximum exposure time can be up to20 s due to precise pointing and image stabilization *** the three telescopes of LST,SCI is a dual-waveband coronagraph simultaneously and independently observing the inner corona in the HI Lyα(121.6±10 nm)line and white light(WL)(700±40 nm)wavebands by using a narrowband Lyαbeam splitter and has a field of view(FOV)from 1.1 to 2.5 R⊙.The stray-light suppression level can attainline and 360.0 nm wavebands,respectively,which adopt an off-axis two-mirror reflective structure with an FOV up to 1.2 R⊙,covering the inner coronal edge area and relating to coronal *** present the up-to-date design for the LST payload.

关键词： telescopes—instrumentation high angular resolution—Sun flares—Sun coronal mass ejections(CMEs)—Sun UV radiation

Treatment and surveillance for non-muscle-invasive bladder cancer:a clinical practice guideline(2021 edition)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2023年第2期10卷 141-161页

作者： Ying-Hui Jin xian-Tao Zeng Tong-Zu liu Zhi-ming Bai Zhong-ling Dou De-Gang Ding Zhi-lu Fan Ping Han Yi-Ran Huang xing Huang ming li xiao-Dong li Yi-Ning li Xu-Hui li Chao-Zhao liang Jiu-Min liu Hong-Shun Ma Juan Qi Jia-Qi shi Jian Wang De-lin Wang Zhi-Ping Wang yun-yun Wang Yong-Bo Wang Qiang Wei hai-Bo xia Jin-Chun xing Si-yu yan Xue-Pei Zhang Guo-You Zheng Nian-Zeng xing Da-lin He xing-Huan Wang on behalf of the Chinese Urological Doctor Association(CUDA),Urological Association of Chinese Research Hospital Association(CRHA-UA),Uro-Health Promotive Association of China International Exchange,Promotive Association for Medical,Health Care(CPAM-UHPA) Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Urology Haikou People’s HospitalHaikou Afliated Hospital of Central South University Xiangya School of MedicineHaikou 570208China Department of Urology the First Afliated Hospital and College of Clinical MedicineHenan University of Science and TechnologyLuoyang 450052HenanChina Department of Urology Henan Provincial People’s Hospi-talZhengzhou University People’s HospitalZhengzhou 450003China Department of Urology the Second Hospital of Dalian Medical UniversityDalian 116023LiaoningChina Department of Urology Institute of UrologyWest China HospitalSichuan UniversityChengdu 610041China Department of Urology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200120China Department of Urology the People’s Hos-pital of Xinjiang Uygur Autonomous RegionUrumqi 830002China Depart-ment of Urology Huaihe Hospital of Henan UniversityKaifeng 475000HenanChina Institutes of Evidence-Based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Urology the Second Afliated Hospital and Second Clinical Medical College of Fujian Medical UniversityQuanzhou 362000FujianChina Department of Urol-ogy the First Afliated Hospital of Anhui Medical UniversityHefei 230022China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou 510080China Department of Urology Tianjin First Central HospitalTianjin 300190China Department of Urology Xinhua HospitalSchool of MedicineShanghai Jiao Tong University School of MedicineShanghai 200092China Department of Urology Afliated Hospital of Guizhou Medical UniversityGuiyang 550004China Department of Urology Qinghai University Afliated HospitalXining 810012China Department of Urology the First Afliated Hospital of Chongqing Medical Univ

Non-muscle invasive bladder cancer(NMIBC)is a major type of bladder cancer with a high incidence worldwide,resulting in a great disease *** and surveillance are the most important part of NIMBC *** 2018,we issued“Treatment and surveillance for non-muscle-invasive bladder cancer in China:an evidencebased clinical practice guideline”.Since then,various studies on the treatment and surveillance of NMIBC have been *** is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in *** a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore *** formed a working group of clinical experts and *** questionnaire investigation of clinicians including primary medical institutions,24 clinically concerned issues,involving transurethral resection of bladder tumor(TURBT),intravesical chemotherapy and intravesical immunotherapy of NMIBC,and follow-up and surveillance of the NMIBC patients,were determined for this *** and recommendations on the management of NMIBC in databases,guideline development professional societies and monographs were referred to,and the European Association of Urology was used to assess the certainty of generated ***,we issued 29 statements,among which 22 were strong recommendations,and 7 were weak *** recommendations cover the topics of TURBT,postoperative chemotherapy after TURBT,Bacillus Calmette–Guérin(BCG)immunotherapy after TURBT,combination treatment of BCG and chemotherapy after TURBT,treatment of carcinoma in situ,radical cystectomy,treatment of NMIBC recurrence,and follow-up and *** hope these recommendations can help promote the treatment and surveillance of NMIBC in China,especially for the primary medical institutions.

关键词： Non-muscle invasive bladder cancer Bladder cancer Transurethral resection of bladder tumor Treatment Surveillance Guideline

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2021年第9期41卷 889-903页

作者： yuankai shi Kaijian Lei yuming Jia Bingqiang Ni Zhiyong He minghong Bi xicheng Wang Jianhua shi ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu lianke liu Zhongliang Guo Yong liu Junquan yang Ke Wang Ke xiao linWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng shi Tiegang tang yan Wang Puyuan xing Dongqing Lv Wangjun liao Zhiguo luo Bin Wang xiaohong Wu xiaoli Zhu Shuhua Han Qisen Guo Rongyu liu Zhiwei lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong liu Hong lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng liu Wensheng Qiu Feng Ye yan yu yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang yanju Chen yuan Chen Hongbing Duan Manxiang li Shengming liu lijun Ma Hongming Pan xia yuan Xueli yuan yulong Zheng Emei Gao li Zhao Shumin Wang Can Wu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China Department of Oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China Department of Oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China Department of Thoracic Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Oncology Department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China Department of Oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China Department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Thoracic Surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China Department of Internal Medicine-Oncology/Department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The Second Department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China Department of Oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine Department Shanghai East HospitalShanghai 200120P.R.China The Second Department of Internal Medicine-Oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China Oncology Department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine Department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic Surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory Department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor

Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2016年第7期129卷 757-762页

作者： Ping liu yan Zhao Zhang-Lei Mu Qian-Jin lu Qian-Jin L U li Zhang Xu Yao Min Zheng Yi-Wen tang xin-xiano lu xiu-Juan xia You-Kun lin yu-Zhen li Cai-xia Tu Zhi-Rong Yao Jin-Hua Xu Wei li Wei Lai Hui-Min yang Hong-Fu xie xiu-Ping Han Zhi-Qiang xie xiang Nong Zai-Pei Guo Dan-Qi Deng Tong-xin shi Jian-Zhong Zhang Department of Dermatology Peking University People's Hospital Beijing 100044 China Department of Dermatology The Second Xiangya Hospital of Central South University Changsha Hunan 410011 China Department of Dermatology The First Hospital of China Medical University Shenyang Liaoning 110001 China Department of Dermatology Institute of Dermatology Chinese Academy of Medical Sciences Nanjing Jiangsu 210042 China Department of Dermatology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China Department of Dermatology Tianjin Changzheng Hospital Tianjin 300120 China Department of Dermatology The Affiliated Hospital of Inner Mongolia Medical University Hohhot Inner Mongolia 010050 China Department of Dermatology Yantai Yuhuangding Hospital Yantai Shandong 264000 China Department of Dermatology The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi 530021 China Department of Dermatology The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Dermatology The Second Hospital of Dalian Medical University Dalian Liaoning 116023 China Department of Dermatology Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai 200092 China Department of Dermatology Shanghai Huashan Hospital Shanghai 200040 China Department of Dermatology Xijing Hospital Xi'an Shaanxi 710032 China Department of Dermatology The Third Affiliated Hospital Of Sun Yat-sen University Guangzhou Guangdong 510630 China Department of Dermatology The Second Hospital of Heilongjiang Province Harbin Heilongjiang 150010 China Department of Dermatology Xiangya Hospital of Central South University Changsha Hunan 410008 China Department of Dermatology.Shengjing Hospital of China Medical University Shenyang Liaoning 110004 China Department of Dermatology Peking University Third Hospital Beijing 100191 China Department of Dermatology The First Affili

Background： Atopic dermatitis （AD） is an inflammatory skin disease characterized by chronic recurrent dermatitis with profound itching. Most patients have personal and/or family history of atopic diseases. Several criteria have been proposed for the diagnosis of AD. Although the clinical features of childhood AD have been widely studied, there has been less large-scale study on adult/adolescent AD. The aim of this study was to investigate the clinical features of adult/adolescent patients with chronic symmetrical eczemaJAD and to propose Chinese diagnostic criteria for adult/adolescent AD. Methods： A hospital-based study was performed. Forty-two dermatological centers participated in this study. Adult and adolescent patients （12 years and over） with chronic symmetrical eczema or AD were included in this study. Questionnaires were completed by both patients and-investigators. The valid questionnaires were analyzed using EpiData 3.1 and SPSS 17.0 software. Results： A total of 2662 valid questionnaires were collected （1369 male and 1293 female）. Of all 2662 patients, 2062 （77.5%） patients had the disease after 12 years old, while only 600 （22.5%） patients had the disease before 12 years old, suggesting late-onset eczema/AD is common. Two thousand one hundred and thirty-nine （80.4%） patients had the disease for more than 6 months. One thousand one hundred and forty-four （43.0%） patients had a personal and/or family history of atopic diseases. One thousand five hundred and forty-eight （58.2%） patients had an elevated total serum IgE and/or eosinophilia and/or positive allergen-specific IgE. Based on these clinical and laboratory features, we proposed Chinese criteria for adult/adolescent AD. Of all 2662 patients, 60.3% were satisfied with our criteria, while only 48.2% satisfied with Hanifin Rajka criteria and 32.7% satisfied with Williams criteria, suggesting a good sensitivity of our criteria in adult/adolescent AD patients. Conclusion： Late-onset of eczema or AD is co

关键词： Adolescents and Adults Atopic Dermatitis Clinical Features Diagnostic Criteria Eczema